Tesamorelin and Oral Dosing: Why There Is No Answer to Give

By What Peptides Editorial Team · Updated 2026-09-14 · Part of Peptide Handling Guides: Reconstitution Arithmetic, Storage and Testing

The direct answer is that there is no oral amount for us to give, and none should be inferred from the existence of this page. We publish no amounts for people or animals, for any peptide, by any route. What follows explains why oral administration is a poor fit for peptides of this size, what the approved tesamorelin product actually is, and where legitimate information about amounts would come from if it applied to you. This is educational context about peptide chemistry and documentation, not medical advice.

Tesamorelin is an analogue of growth hormone-releasing hormone, published descriptions placing it at 44 residues with a molecular weight around 5 kDa, and a tesamorelin product was approved by the FDA in 2010 for HIV-associated lipodystrophy as an injectable formulation. Being oral is not something a dose becomes by being discussed; it is a property of a finished pharmaceutical product that a regulator evaluated. Material online is typically labelled research use only, not for human consumption. See how a peptide is defined and how to read a tesamorelin document.

Three Barriers Between a Swallowed Peptide and the Bloodstream

The first barrier is acid and enzyme. The stomach is a strongly acidic compartment whose purpose includes unfolding and beginning digestion, and proteinases such as pepsin cleave peptide bonds there. A peptide bond is an amide linkage between the carboxyl carbon of one residue and the amine nitrogen of the next, and hydrolysing it requires water plus acid, base, enzymes or sustained heat, all of which the upper gastrointestinal tract supplies readily. Proteolysis is not a special case here; it is the normal fate of dietary protein.

The second barrier is enzymatic attack further down. Trypsin cleaves on the carboxyl side of lysine and arginine except when proline follows, chymotrypsin targets aromatic residues, and brush-border peptidases finish the job into single residues, dipeptides and tripeptides. A chain of 44 residues presents many such cleavage sites. What leaves the lumen is overwhelmingly fragments and free amino acids rather than intact molecule, which is why absorption is measured for fragments rather than for the parent peptide.

The third barrier is the epithelium itself. Crossing the intestinal lining requires passing a mucus layer, then either squeezing between cells or passing through them. Paracellular passage is size-limited, transcellular passage requires lipophilicity most peptides lack, and the tight junctions restrict what moves between cells. A molecule around 5 kDa with many hydrogen-bond donors is close to the opposite of what crosses a membrane passively. Specialised carriers exist for very small peptides such as di- and tripeptides, not for chains of this length.

What This Means for Records and Expectations

The practical consequence is that route of administration is a property of a finished formulation, not a preference. Oral peptide products that exist generally depend on engineered solutions: protection from enzymatic attack, absorption enhancers, enteric coatings, protease inhibitors in the formulation, or chemical modification such as cyclisation, N-methylation or lipidation. Those are product design decisions evaluated in clinical programmes and reviewed by regulators, and none of them can be reproduced by reading about arithmetic.

The second consequence concerns how any claim should be recorded. If a document describes a peptide as orally available, the meaningful questions are what evidence supports it and how it was measured: plasma concentrations after oral administration, comparison against another route, or measured bioavailability as a percentage. A claim without a method is a marketing statement. The arithmetic skills in this cluster, such as converting mg to mcg and computing concentration, cannot substitute for that evidence and were never intended to.

The third consequence is simply about reading search results honestly. A page optimised for an oral-dose keyword is not obliged to answer the question, and most pages that do answer it should be treated with suspicion, because legitimate answers exist only for products that went through approval. Where no such product exists for a route, the absence is information. Anything with oral instructions attached to research material labelled not for human consumption is combining two categories that should have stayed apart.

What the Approved Product Is, and Where Amounts Come From

The approved tesamorelin product is an injectable formulation, supplied with its own prescribing information stating strength, presentation, storage conditions and the conditions of use a regulator assessed. Injectable here is not an instruction; it is a description of what the approved medicine is. Where nothing exists that a regulator has evaluated for a different route, no amount for that route can be responsibly stated, and none should be assembled by analogy from a document describing something else.

So, explicitly and without qualification: this page provides no oral amount, no amount by any other route, no frequency, no schedule and no process by which one could be derived. If tesamorelin is relevant to your care, the only appropriate sources are the approved prescribing information, a licensed clinician who knows your history, and your national regulator. Those three can weigh factors no website can see, and they are also the only route by which lawful supply exists in most jurisdictions.

What you can take away from here is chemistry rather than a number. Peptides are chains of amino acids joined by amide bonds; those bonds hydrolyse under conditions the gut provides easily; intact absorption across the intestinal epithelium is difficult for large polar molecules; and making it work is a formulation problem solved in a laboratory and reviewed by a regulator. Understanding that is enough to judge any oral claim you read later. See the documentation guides and why injection-safety questions resolve into sterility and regulation.

• Peptide bonds hydrolyse under acidic, basic, enzymatic or thermal conditions; the gut supplies all of them.
• Tesamorelin is described at about 44 residues and roughly 5 kDa, far above sizes crossing passively.
• Trypsin cleaves after lysine and arginine except before proline; many such sites exist in longer chains.
• Oral delivery, where it works, is an engineered formulation outcome assessed by a regulator.
• Legitimate information about amounts comes from prescribing information, a clinician and the regulator.

This page is part of the Peptide Handling Guides: Reconstitution Arithmetic, Storage and Testing guide.